YieldMax MRNA Option Income Strategy ETF (MRNY)

This instrument is a classic 'value trap' wrapped in a high-yield ETF structure. The long-term rating is severely compromised because the underlying asset has suffered an 82% collapse in just one year, a trajectory that signals a broken business model or a permanent loss of utility for the option income strategy. While the headline yield appears astronomical, it is largely a reflection of the share price implosion rather than sustainable cash flow; the recent dividend history shows erratic, fluctuating payouts that do not provide the stability required for a reliable income vehicle. Short-term, the stock is hovering near its 52-week lows, offering some technical relief, but the statistical forecast offers no directional edge, and the options market is pricing in continued uncertainty rather than a recovery. Investors chasing the yield here are likely buying a shrinking asset class with no clear path to restoration.